This program offers a comprehensive exploration of advanced clear cell renal cell carcinoma (RCC) management, focusing on approved frontline combinations of immunotherapy and/or targeted therapy, insights into HIF2-alpha involvement in RCC pathogenesis, and strategies for managing treatment-related adverse events.
- Provider:Horizon CME, Inc.
- Activity Link: http://default/node/1482
- Start Date: 2024-04-19 05:00:00
- End Date: 2024-04-19 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest